Top

Published in:

01-04-2015 | Review Article

Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment

Authors: Katherine Semenkovich, Miriam E. Brown, Dragan M. Svrakic, Patrick J. Lustman

Published in: Drugs | Issue 6/2015

Abstract

Clinically significant depression is present in one of every four people with type 2 diabetes mellitus (T2DM). Depression increases the risk of the development of T2DM and the subsequent risks of hyperglycemia, insulin resistance, and micro- and macrovascular complications. Conversely, a diagnosis of T2DM increases the risk of incident depression and can contribute to a more severe course of depression. This linkage reflects a shared etiology consisting of complex bidirectional interactions among multiple variables, a process that may include autonomic and neurohormonal dysregulation, weight gain, inflammation, and hippocampal structural alterations. Two recent meta-analyses of randomized controlled depression treatment trials in patients with T2DM concluded that psychotherapy and antidepressant medication (ADM) were each moderately effective for depression and that cognitive behavior therapy (CBT) had beneficial effects on glycemic control. However, the number of studies (and patients exposed to randomized treatment) included in these analyses is extremely small and limits the certainty of conclusions that can be drawn from the data. Ultimately, there is no escaping the paucity of the evidence base and the need for additional controlled trials that specifically address depression management in T2DM. Future trials should determine both the effects of treatment and the change in depression during treatment on measures of mood, glycemic control, and medical outcome.

Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.

Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40. doi:10.1016/S0140-6736(11)60679-X.PubMedCrossRef

Okoro CA, Denny CH, Greenlund KJ, Benjamin SM, Strine TW, Balluz LS, et al. Risk factors for heart disease and stroke among diabetic persons, by disability status. J Diabetes Complicat. 2005;19(4):201–6.PubMedCrossRef

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRef

Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105.

The World Health Organization. The Global Burden of Disease: 2004 Update. 2008.

Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med. 1997;59(3):241–50.PubMedCrossRef

Geringer E. Affective disorders and diabetes mellitus. Neuropsychological and behavioral aspects of diabetes. New York: Springer; 1990.

Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57–63.PubMedCrossRef

10.

Freedland KE, Skala JA, Carney RM, Raczynski JM, Taylor CB, Mendes de Leon CF, et al. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity. Psychosom Med. 2002;64(6):897–905.PubMed

11.

Lustman PJ, Clouse RE, Carney RM. Depression and the reporting of diabetes symptoms. Int J Psychiatry Med. 1988;18(4):295–303.PubMedCrossRef

12.

Weyerer S, Hewer W, Pfeifer-Kurda M, Dilling H. Psychiatric disorders and diabetes–results from a community study. J Psychosom Res. 1989;33(5):633–40.PubMedCrossRef

13.

Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24(6):1069–78.PubMedCrossRef

14.

Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23(11):1165–73. doi:10.1111/j.1464-5491.2006.01943.x.PubMedCrossRef

15.

Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases risk of type 2 diabetes in younger adults. Diabetes Care. 2005;28(5):1063–7.PubMedCrossRef

16.

Campayo A, de Jonge P, Roy JF, Saz P, de la Camara C, Quintanilla MA, et al. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am J Psychiatry. 2010;167(5):580–8. doi:10.1176/appi.ajp.2009.09010038.PubMedCrossRef

17.

Arroyo C, Hu FB, Ryan LM, Kawachi I, Colditz GA, Speizer FE, et al. Depressive symptoms and risk of type 2 diabetes in women. Diabetes Care. 2004;27(1):129–33.PubMedCrossRef

18.

Kumari M, Head J, Marmot M. Prospective study of social and other risk factors for incidence of type 2 diabetes in the Whitehall II study. Arch Int Medicine. 2004;164(17):1873–80. doi:10.1001/archinte.164.17.1873.CrossRef

19.

Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care. 1996;19(10):1097–102.PubMedCrossRef

20.

Everson-Rose SA, Meyer PM, Powell LH, Pandey D, Torrens JI, Kravitz HM, et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care. 2004;27(12):2856–62.PubMedCrossRef

21.

Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Power E. Type 2 diabetes mellitus as a risk factor for depression: a systematic review and meta-analysis. Diabetologia. 2010;53:2480–6.PubMedCentralPubMedCrossRef

22.

Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008;31(12):2383–90. doi:10.2337/dc08-0985.PubMedCentralPubMedCrossRef

23.

Pan A, Sun Q, Okereke OI, Rexrode KM, Rubin RR, Lucas M. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia. 2012;55:62–72.CrossRef

24.

McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Exp Opin Drug Saf. 2006;5(1):157–68. doi:10.1517/14740338.5.1.157.CrossRef

25.

Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry. 2009;166:591–8.PubMedCrossRef

26.

Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980–91. doi:10.1176/appi.ajp.2009.09030312.PubMedCrossRef

27.

Stahl SM. Stahl’s essential psychopharmacology : neuroscientific basis and practical applications. 3rd ed. Fully rev. and expanded ed. Cambridge: Cambridge University Press; 2008.

28.

Gerhard T, Akincigil A, Correll CU, Foglio NJ, Crystal S, Olfson M. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry. 2014;75(5):490–7. doi:10.4088/JCP.13m08675.PubMedCrossRef

29.

Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–9. doi:10.1001/archgenpsychiatry.2010.2.PubMedCrossRef

30.

Strine TW, Mokdad AH, Dube SR, Balluz LS, Gonzalez O, Berry JT, Manderscheid R, Kroenke K. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry. 2008;30:127–37.PubMedCrossRef

31.

Skilton MR, Moulin P, Terra J, Bonnet F. Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry. 2007;62:1251–7.PubMedCrossRef

32.

Pan A, Lucas M, Sun Q, van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu FB. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Int Med. 2010;170(21):1884–91.CrossRef

33.

Patterson ZR, Khazall R, Mackay H, Anisman H, Abizaid A. Central ghrelin signaling mediates the metabolic response of C57BL/6 male mice to chronic social defeat stress. Endocrinology. 2013;154(3):1080–91. doi:10.1210/en.2012-1834.PubMedCrossRef

34.

Becker C, Zeau B, Rivat C, Blugeot A, Hamon M, Benoliel JJ. Repeated social defeat-induced depression-like behavioral and biological alterations in rats: involvement of cholecystokinin. Mol Psychiatry. 2008;13(12):1079–92. doi:10.1038/sj.mp.4002097.PubMedCrossRef

35.

Wilkinson MB, Dias C, Magida J, Mazei-Robison M, Lobo M, Kennedy P, et al. A novel role of the WNT-dishevelled-GSK3beta signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. J Neurosci. 2011;31(25):9084–92. doi:10.1523/JNEUROSCI.0039-11.2011.PubMedCentralPubMedCrossRef

36.

Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes. 2000;108(3):187–90. doi:10.1055/s-2000-7742.PubMedCrossRef

37.

Axelson DA, Doraiswamy PM, McDonald WM, Boyko OB, Tupler LA, Patterson LJ, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res. 1993;47(2):163–73.PubMedCrossRef

38.

Vogelzangs N, Suthers K, Ferrucci L, Simonsick EM, Ble A, Schrager M, et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology. 2007;32(2):151–9. doi:10.1016/j.psyneuen.2006.11.009.PubMedCentralPubMedCrossRef

39.

Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. 2008;31(9):464–8. doi:10.1016/j.tins.2008.06.006.PubMedCrossRef

40.

Jacobson L, Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev. 1991;12(2):118–34. doi:10.1210/edrv-12-2-118.PubMedCrossRef

41.

Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature. 2011;476(7361):458–61. doi:10.1038/nature10287.PubMedCentralPubMedCrossRef

42.

Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, et al. Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res. 2007;41(7):553–60. doi:10.1016/j.jpsychires.2006.06.011.PubMedCrossRef

43.

Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev. 2013;37(8):1346–62. doi:10.1016/j.neubiorev.2013.03.010.PubMedCentralPubMedCrossRef

44.

Bruehl H, Wolf OT, Convit A. A blunted cortisol awakening response and hippocampal atrophy in type 2 diabetes mellitus. Psychoneuroendocrinology. 2009;34(6):815–21. doi:10.1016/j.psyneuen.2008.12.010.PubMedCentralPubMedCrossRef

45.

Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care. 2000;23(7):934–42.PubMedCrossRef

46.

De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ. Association of depression and diabetes complications: a meta-analysis. Psychosom Med. 2001;63:619–30.PubMedCrossRef

47.

Wexler DJ, Grant RW, Wittenberg E, Bosch JL, Cagliero E, Delahanty L, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49(7):1489–97. doi:10.1007/s00125-006-0249-9.PubMedCrossRef

48.

Egede LE, Hernández-Tejada MA. Effect of comorbid depression on quality of life in adults with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):83–91.PubMedCrossRef

49.

Anderson BJ, Edelstein S, Abramson NW, Levitt Katz LE, Yasuda PM, Lavietes SJ, Trief PM, Tollefson SE. Depressive symptoms and quality of life in adolescents with type 2 diabetes. Diabetes Care. 2011;34:2205–7.PubMedCentralPubMedCrossRef

50.

Schmitz N, Gariepy G, Smith KJ, Clyde M, Malla A, Boyer R, et al. Recurrent subthreshold depression in type 2 diabetes: an important risk factor for poor health outcomes. Diabetes Care. 2014;37(4):970–8. doi:10.2337/dc13-1832.PubMedCrossRef

51.

Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28(3):626–31.PubMedCrossRef

52.

Lin EH, Katon W, Von Korff M, Rutter C, Simon GE, Oliver M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27(9):2154–60.PubMedCrossRef

53.

Gonzalez JS, Safren SA, Cagliero E, Wexler DJ, Delahanty L, Wittenberg E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care. 2007;30(9):2222–7. doi:10.2337/dc07-0158.PubMedCrossRef

54.

Ciechanowski PS, Katon WJ, Russo JE, Hirsch IB. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen Hosp Psychiatry. 2003;25(4):246–52.PubMedCrossRef

55.

Gonzalez JS, Schneider HE, Wexler DJ, Psaros C, Delahanty LM, Cagliero E, et al. Validity of medication adherence self-reports in adults with type 2 diabetes. Diabetes Care. 2013;36(4):831–7. doi:10.2337/dc12-0410.PubMedCentralPubMedCrossRef

56.

Naranjo DM, Fisher L, Arean PA, Hessler D, Mullan J. Patients with type 2 diabetes at risk for major depressive disorder over time. Ann Fam Med. 2011;9:115–20.PubMedCentralPubMedCrossRef

57.

Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.PubMedCentralPubMedCrossRef

58.

Lin EH, Rutter CM, Katon W, Heckbert SR, Ciechanowski P, Oliver MM, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33(2):264–9. doi:10.2337/dc09-1068.PubMedCentralPubMedCrossRef

59.

Clouse RE, Lustman PJ, Freedland KE, Griffith LS, McGill JB, Carney RM. Depression and coronary heart disease in women with diabetes. Psychosom Med. 2003;65(3):376–83.PubMedCrossRef

60.

Sieu N, Katon W, Lin EH, Russo J, Ludman E, Ciechanowski P. Depression and incident diabetic retinopathy: a prospective cohort study. Gen Hosp Psychiatry. 2011;33(5):429–35. doi:10.1016/j.genhosppsych.2011.05.021.PubMedCentralPubMedCrossRef

61.

Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care. 2005;28(6):1339–45.PubMedCrossRef

62.

Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS. Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol. 2005;161(7):652–60. doi:10.1093/aje/kwi089.PubMedCrossRef

63.

Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28(11):2668–72.PubMedCrossRef

64.

Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. Cochrane Database Syst Rev. 2012;12:CD008381. doi:10.1002/14651858.CD008381.pub2.

65.

Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff. 2011;30(8):1434–42. doi:10.1377/hlthaff.2010.1024.CrossRef

66.

Charney DS, Nemeroff CB, Lewis L, Laden SK, Gorman JM, Laska EM, et al. National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. Arch Gen Psychiatry. 2002;59(3):262–70.PubMedCrossRef

67.

Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005–2008. NCHS data brief. 2011;76:1–8.PubMed

68.

Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848–56. doi:10.1001/archgenpsychiatry.2009.81.PubMedCrossRef

69.

Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ. 2009;339:b3999. doi:10.1136/bmj.b3999.PubMedCentralPubMedCrossRef

70.

Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ. 2005;331(7509):155–7. doi:10.1136/bmj.331.7509.155.PubMedCentralPubMedCrossRef

71.

Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45. doi:10.1371/journal.pmed.0050045.PubMedCentralPubMedCrossRef

72.

Kirsch I. Antidepressant drugs ‘work’, but they are not clinically effective. Br J Hosp Med (Lond). 2008;69(6):359.CrossRef

73.

Kirsch I, Moore TJ, Scoboria A, Nichols SS. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat. 2002;5:23.

74.

Kirsch I. Review: benefits of antidepressants over placebo limited except in very severe depression. Evid Based Ment Health. 2010;13(2):49. doi:10.1136/ebmh.13.2.49.PubMedCrossRef

75.

Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012;28(1):27–39. doi:10.1185/03007995.2011.628303.PubMedCrossRef

76.

Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(10):1157–64. doi:10.1001/jamapsychiatry.2014.1054.PubMedCentralPubMedCrossRef

77.

Hollon SD, Ponniah K. A review of empirically supported psychological therapies for mood disorders in adults. Depress Anxiety. 2010;27(10):891–932. doi:10.1002/da.20741.PubMedCentralPubMedCrossRef

78.

Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203–9.PubMedCrossRef

79.

Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009;70(9):1219–29. doi:10.4088/JCP.09r05021.PubMedCrossRef

80.

Cuijpers P, van Straten A, Hollon SD, Andersson G. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis. Acta psychiatr Scand. 2010;121(6):415–23. doi:10.1111/j.1600-0447.2009.01513.x.PubMedCrossRef

81.

van der Feltz-Cornelis CM, Nuyen J, Stoop C, Chan J, Jacobson AM, Katon W, et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2010;32(4):380–95. doi:10.1016/j.genhosppsych.2010.03.011.PubMedCrossRef

82.

Walker EHA, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med. 2008;75(6):431–9.PubMedCrossRef

83.

Echeverry D, Duran P, Bonds C, Lee M, Davidson MB. Effect of pharmacological treatment of depression on A1C and quality of life in low-income Hispanics and African Americans with diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2009;32(12):2156–60. doi:10.2337/dc09-0785.PubMedCentralPubMedCrossRef

84.

Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000;23(5):618–23.PubMedCrossRef

85.

Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam Pract. 2003;4:7. doi:10.1186/1471-2296-4-7.PubMedCentralPubMedCrossRef

86.

Paile-Hyvarinen M, Wahlbeck K, Eriksson JG. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. BMC Fam Pract. 2007;8:34. doi:10.1186/1471-2296-8-34.PubMedCentralPubMedCrossRef

87.

Xue H. Paroxetine for depression in diabetes: a randomized controlled trial. Chin Mental Health J. 2004;18(10):735–7.

88.

Welton NJ. Evidence synthesis for decision making in healthcare. Chichester: Wiley; 2012.CrossRef

89.

Murphy GE, Carney RM, Knesevich MA, Wetzel RD, Whitworth P. Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression. Psychol Rep. 1995;77(2):403–20. doi:10.2466/pr0.1995.77.2.403.PubMedCrossRef

90.

Ellis AE, Grieger RM. Handbook of rational-emotive therapy. New York: Springer; 1986.

91.

Beck AT, Steer RA, Carbin MG. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77–100.CrossRef

92.

Hollon SD, Kendall PC, Lumry A. Specificity of depressotypic cognitions in clinical depression. J Abnorm Psychol. 1986;95(1):52–9.PubMedCrossRef

93.

Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Int Med. 1998;129(8):613–21.PubMedCrossRef

94.

Lustman PJ, Freedland KE, Griffith LS, Clouse RE. Predicting response to cognitive behavior therapy of depression in type 2 diabetes. Gen Hosp Psychiatry. 1998;20(5):302–6.PubMedCrossRef

95.

American Diabetes A. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–80. doi:10.2337/dc14-S014.CrossRef

96.

Markowitz SM, Gonzalez JS, Wilkinson JL, Safren SA. A review of treating depression in diabetes: emerging findings. Psychosomatics. 2011;52(1):1–18. doi:10.1016/j.psym.2010.11.007.PubMedCentralPubMedCrossRef

97.

Van Bastelaar KMP, Pouwer F, Cuijpers P, Riper H, Snoek FJ. Web-based depression treatment for type 1 and type 2 diabetic patients. Diabetes Care. 2011;34:320–5.PubMedCentralPubMedCrossRef

98.

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. doi:10.1176/appi.ajp.163.1.28.PubMedCrossRef

Title: Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment
Authors: Katherine Semenkovich
Miriam E. Brown
Dragan M. Svrakic
Patrick J. Lustman
Publication date: 01-04-2015
Publisher: Springer International Publishing
Published in: Drugs / Issue 6/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-015-0347-4

At a glance: The STEP trials

Springer Medicine

Depression in Type 2 Diabetes Mellitus: Prevalence, Impact, and Treatment

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

Finafloxacin: First Global Approval

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

Panobinostat: First Global Approval

Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes

Clinical Association Between Pharmacogenomics and Adverse Drug Reactions

Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C